Health Care • Biotechnology: Pharmaceutical Preparations
$1.15 ▼ -0.02
(-1.71%)
MKT CAP: $133.6M • VOL: 2.31M
52W L $1 52W H $6
ROARABLE / RQD
D- • 37/100
PIOTROSKI
2 / 9
CATX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$113.6M | -$90.9M | -$40.9M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$103.1M | -$79.3M | -$46.5M |
| EBITDA (Normalized) | -$103.4M | -$47.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$82.5M | -$18.3M | -$36.9M |
| Capital Expenditures (CapEx) | $12.7M | $54.4M | — |
| Free Cash Flow (FCF) | -$95.2M | -$72.7M | -$36.9M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -31.3% | — |
| Cash & Short-Term Equivalents | $30.6M | $61.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $207.0M | $290.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CATX.